Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jade: Esmirtazapine Safety in Elderly Insomnia
NCT00561574Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Primary completion
- Feb 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of esmirtazapine in Chronic Primary Insomnia (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience at Least One Adverse Event up to 53 weeks, Number of Participants Who Discontinue Study Drug Due to an AE up to 52 weeks and 4 more. Started Jan 2008; status: completed.
02
Drugs
esmirtazapine
03
Conditions
Chronic Primary Insomnia
Beyond the preview
Go deeper on NCT00561574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561574.